Skip to main content

Advertisement

Table 3 Prevalence and demographic correlates of disease burden and treatment burden

From: Adding patient-reported outcomes to a multisite registry to quantify quality of life and experiences of disease and treatment for youth with juvenile idiopathic arthritis

  Disease burden Treatment burden
Pain interference T-scorea Morning stiffness Serious medication side effect Intolerance to methotrexateb
Mean (SD) % >15 mins % Yes % Intolerant
Total (N = 180) 50.1 (11.1) 17.8% 26.7% 42.2%
Disease duration
  > 8 years 50.3 (11.8) 24.0% 32.0% 41.9%
  ≤ 8 years 49.9 (10.6) 13.3% 22.9% 42.4%
p-value 0.8676 0.0650 0.1715 0.9682
Age group
  ≥ 13 years 51.3 (11.7) 25.3% 39.2% 40.0%
  < 13 years 49.1 (10.5) 11.9% 16.8% 43.6%
p-value 0.1481 0.0193 0.0007 0.7335
Sex
 Female 50.3 (11.1) 18.1% 26.1% 48.5%
 Male 49.3 (11.1) 16.7% 28.6% 22.7%
p-value 0.5835 0.8297 0.7499 0.0332
Race/Ethnicity
 White non-Hispanic 49.2 (10.7) 19.2% 26.7% 40.6%
 Other 53.8 (12.0) 11.8% 26.5% 47.6%
p-value 0.0266 0.3086 0.9771 0.5674
Highest parental education
  ≤ High school graduate 50.2 (10.6) 22.9% 27.1% 42.9%
 Any college 50.0 (11.3) 15.9% 26.5% 42.0%
p-value 0.7779 0.2768 0.9392 0.9464
  1. Data are presented as mean and standard deviation (SD) for pain interference and as row percentages for other outcomes
  2. P-values derived from the chi-squared (χ2) or Wilcoxon tests
  3. Disease duration was dichotomized using the sample mean rounded to the nearest integer as the cut point
  4. aRaw pain interference scores were transformed into a ‘T-score’ for each participant. The T-score rescales the raw score into a standardized score with a mean of 50, standard deviation of 10, and possible range of 38–78
  5. bIntolerance to methotrexate was assessed only among those who were on methotrexate (N = 90)